 <h1>Zinacef Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>cefuroxime</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about cefuroxime. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Zinacef.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cefuroxime: oral powder for suspension, oral tablet</i></p><p>Other dosage forms:</p><ul><li>powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cefuroxime (the active ingredient contained in Zinacef) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cefuroxime:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>diarrhea</li>
<li>fever</li>
<li>general feeling of illness or discomfort</li>
<li>headache</li>
<li>itching of the vagina or genital area</li>
<li>pain during sexual intercourse</li>
<li>rigidity</li>
<li>sweating</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chest pain</li>
<li>cough</li>
<li>loose stools</li>
<li>painful or difficult urination</li>
<li>shortness of breath</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>bloody or cloudy urine</li>
<li>body aches or pain</li>
<li>burning while urinating</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>ear congestion</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>frequent urge to urinate</li>
<li>general body swelling</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nasal congestion</li>
<li>nausea or vomiting</li>
<li>nosebleeds</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>pale skin</li>
<li>pink or red urine</li>
<li>sneezing</li>
<li>stuffy or runny nose</li>
<li>swelling of the joints</li>
<li>swollen glands</li>
<li>tightness of chest or wheezing</li>
<li>white or brownish vaginal discharge</li>
<li>white patches in the mouth or throat or on the tongue</li>
<li>white patches with diaper rash</li>
<li>yellowing of the eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloody, black, or tarry stools</li>
<li>clay-colored stools</li>
<li>cough or hoarseness</li>
<li>coughing up blood</li>
<li>decrease in urine output or decrease in urine-concentrating ability</li>
<li>feeling of discomfort</li>
<li>fever with or without chills</li>
<li>general feeling of tiredness or weakness</li>
<li>high fever</li>
<li>hives</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>light-colored stools</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>swollen lymph glands</li>
<li>swollen or painful glands</li>
<li>unpleasant breath odor</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cefuroxime may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Bad, unusual, or unpleasant (after) taste</li>
<li>change in taste</li>
<li>diaper rash</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach cramps</li>
<li>acid or sour stomach</li>
<li>belching</li>
<li>bloated</li>
<li>difficulty with moving</li>
<li>excess air or gas in the stomach or intestines</li>
<li>flushing or redness of the skin</li>
<li>full feeling</li>
<li>gas in the stomach</li>
<li>heartburn</li>
<li>indigestion</li>
<li>irritability</li>
<li>irritation or soreness of the mouth</li>
<li>itching skin</li>
<li>muscle pain or stiffness</li>
<li>muscle spasm of the neck</li>
<li>passing gas</li>
<li>restlessness</li>
<li>sleepiness or unusual drowsiness</li>
<li>stomach discomfort, upset, or pain</li>
<li>swelling of the tongue</li>
<li>thirst</li>
<li>trouble sitting still</li>
<li>unusually warm skin</li>
<li>watering of the mouth and drooling</li>
<li>weight loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hives or welts</li>
<li>redness of the skin </li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefuroxime: injectable powder for injection, intravenous solution, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>Cefuroxime (the active ingredient contained in Zinacef) was generally well tolerated.  The side effects most commonly reported with the parenteral formulation have included neutropenia, eosinophilia, transient liver enzyme/bilirubin elevations, and injection site reactions.  The side effects most commonly reported with the oral formulations have included Candida overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances, and transient liver enzyme elevations.<sup>[Ref]</sup></p><p>Side effects may be more likely and more severe in patients with liver disease and/or renal dysfunction.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea/loose stools, nausea/vomiting, abdominal pain, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal cramps, flatulence, indigestion, mouth ulcers, swollen tongue, dyspepsia, gastrointestinal (GI) infection, ptyalism/excess salivation, GI disturbance, vomiting</p>
<p><b>Frequency not reported</b>: Abdominal discomfort, dry mouth, Clostridium difficile-associated diarrhea</p>
<p><b>Postmarketing reports</b>: GI disturbances (including diarrhea, nausea, vomiting, abdominal pain), pseudomembranous colitis</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Vomiting, abdominal pain, colitis<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transient increase in AST, transient increase in ALT, transient increase in liver enzyme levels</p>
<p><b>Uncommon</b> (0.1% to 1%): Transient increase in bilirubin</p>
<p><b>Postmarketing reports</b>: Hepatic dysfunction, hepatitis, cholestasis, jaundice (mainly cholestatic)</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Hepatic dysfunction (including cholestasis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Cephalosporin-class antibiotics (including this drug) have been associated with seizures, especially in patients with renal dysfunction when the dose was not reduced.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache, dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Sleepiness, somnolence, hyperactivity</p>
<p><b>Postmarketing reports</b>: Seizures, encephalopathy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Delayed hypersensitivity reaction</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (including rash, pruritus, urticaria)</p>
<p><b>Rare</b> (0.01% to 0.1%): Severe hypersensitivity reactions</p>
<p><b>Frequency not reported</b>: Serum sickness</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, serum sickness-like reaction<sup>[Ref]</sup></p><p>Delayed hypersensitivity reaction to this drug has been reported in 2.9% of patients with history of delayed hypersensitivity to penicillin (but not a cephalosporin).</p>
<p></p>
<p>Rare cases of severe hypersensitivity reactions (including erythema multiforme, toxic epidermal necrolysis [exanthematic necrolysis], drug fever, serum sickness-like reaction, anaphylaxis, Stevens-Johnson syndrome) have been reported.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Eosinophilia, decreased hemoglobin and hematocrit, neutropenia, decreased hemoglobin concentration</p>
<p><b>Uncommon</b> (0.1% to 1%): Positive Coombs test, leukopenia, thrombocytopenia</p>
<p><b>Frequency not reported</b>: Autoimmune granulocytopenia, increased coagulation time</p>
<p><b>Postmarketing reports</b>: Hemolytic anemia, pancytopenia, increased prothrombin time</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis<sup>[Ref]</sup></p><p>Profound leukopenia has sometimes been profound with oral therapy.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Increased BUN, increased creatinine, decreased CrCl, acute renal failure</p>
<p><b>Postmarketing reports</b>: Renal dysfunction, interstitial nephritis (including reversible fever, azotemia, pyuria, eosinophilia)</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Toxic nephropathy<sup>[Ref]</sup></p><p>Acute renal failure has been reported.  Renal function improved after this drug was stopped, and deteriorated upon rechallenge.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vaginitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Vulvar itch, dysuria, vaginal candidiasis, vaginal discharge, vaginal itch, urethral pain/bleeding, kidney pain, urinary tract infection, vaginal irritation</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Vaginitis (including vaginal candidiasis)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Diaper/nappy rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria/hives, pruritus, erythema</p>
<p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, toxic epidermal necrolysis (exanthematic necrolysis), Stevens-Johnson syndrome</p>
<p><b>Frequency not reported</b>: Acute generalized exanthematous pustulosis</p>
<p><b>Postmarketing reports</b>: Angioedema, urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, cutaneous vasculitis<sup>[Ref]</sup></p><p>A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients.  The dermatitis resolved after the nurse stopped preparing the solutions.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p>
<p></p>
<p>Cephalosporin-class:</p>
<p>-Frequency not reported: Urine glucose false positive<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Transient increase in LDH, transient increase in alkaline phosphatase, Candida overgrowth, dislike of taste</p>
<p><b>Uncommon</b> (0.1% to 1%): Chest pain/tightness, chills, thirst, viral illness, candidiasis, fever</p>
<p><b>Rare</b> (0.01% to 0.1%): Drug fever</p>
<p><b>Frequency not reported</b>: Clostridium difficile overgrowth, disulfiram reaction<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Shortness of breath, sinusitis, cough, upper respiratory infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle cramps, muscle stiffness, muscle spasm of the neck, lockjaw-type reaction, joint swelling, arthralgia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Tachycardia</p>
<p><b>Frequency not reported</b>: Kounis syndrome type I variant<sup>[Ref]</sup></p><p>A 90-year-old man, with no history of coronary artery disease, diabetes mellitus, hypertension, or hyperlipidemia, was administered 750 mg cefuroxime axetil IM for urinary tract infection.  About 10 minutes after the injection, the patient developed chest pain and pruritic skin rashes.  Kounis syndrome type I variant was diagnosed secondary to the drug.  Five days after stopping the drug, the patient's symptoms had resolved.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions (including pain, thrombophlebitis), thrombophlebitis with IV administration</p>
<p><b>Frequency not reported</b>: Pain at IM injection site<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Jarisch-Herxheimer reaction<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Irritable behavior</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Bulpitt D, Potter CE, Jaderberg M "A large scale, general practice based investigation into the clinical efficacy and tolerability of cefuroxime axetil in women with uncomplicated urinary tract infect." Curr Med Res Opin 12 (1991): 318-24</p><p id="ref_3">3. Yangco BG, Lowe J, Nolen TM, et al "A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults." Clin Ther 12 (1990): 440-6</p><p id="ref_4">4. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ "Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis." Clin Ther 17 (1995): 861-74</p><p id="ref_5">5. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_6">6. Pines A, Raafat H, Kennedy MR, Mullinger BM "Experience with cefuroxime in 190 patients with severe respiratory infections." Chemotherapy 26 (1980): 212-7</p><p id="ref_7">7. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ "Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis." Antimicrob Agents Chemother 39 (1995): 2528-34</p><p id="ref_8">8. Cannon SR, Dyson PH, Sanderson PJ "Pseudomembranous colitis associated with antibiotic prophylaxis in orthopaedic surgery." J Bone Joint Surg Br 70 (1988): 600-2</p><p id="ref_9">9. Sommers D, Van Wyk M, Williams PE, Harding SM "Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing." Antimicrob Agents Chemother 25 (1984): 344-7</p><p id="ref_10">10. Hebblethwaite EM, Brown GW, Cox DM "A comparison of the efficacy and safety of cefuroxime axetil and augmentin in the treatment of upper respiratory tract infections." Drugs Exp Clin Res 13 (1987): 91-4</p><p id="ref_11">11. Holloway KL, Smith KW, Wilberger JE, Jemsek JG, Giguere GC, Collins JJ "Antibiotic prophylaxis during clean neurosurgery: a large, multicenter study using cefuroxime." Clin Ther 18 (1996): 84-94</p><p id="ref_12">12. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_13">13. Griffiths GK, Vandenburg MJ, Wight LJ, et al "Efficacy and tolerability of cefuroxime axetil in patients with upper respiratory tract infections." Curr Med Res Opin 10 (1987): 555-61</p><p id="ref_14">14. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_15">15. Abramowicz M, Aaron H "Cefuroxime axetil." Med Lett Drugs Ther 30 (1988): 57-9</p><p id="ref_16">16. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ "Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia." J Antimicrob Chemother 37 (1996): 555-64</p><p id="ref_17">17. Baniasadi S,  Fahimi F,  Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):</p><p id="ref_18">18. Romano A, Quaratino D, Venuti A, Venemalm L, Mayorga C, Blanca M "Selective type-1 hypersensitivity to cefuroxime." J Allergy Clin Immunol 101 (1998): 564-5</p><p id="ref_19">19. Saeed SAM, Bazza M, Zaman M, Ryatt KS "Cefuroxime induced lymphomatoid hypersensitivity reaction." Postgrad Med J 76 (2000): 577-9</p><p id="ref_20">20. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226</p><p id="ref_21">21. Viken R, Van Arsdel PP "Allergy to cephalosporins." JAMA 265 (1991): 2254</p><p id="ref_22">22. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p><p id="ref_23">23. Murphy MF, Metcalfe P, Grint PC, et al "Cephalosporin-induced immune neutropenia." Br J Haematol 59 (1985): 9-14</p><p id="ref_24">24. Malloy CA,  Kiss JE,  Challapalli M "Cefuroxime-induced immune hemolysis." J Pediatr 143 (2003): 130-2</p><p id="ref_25">25. Goddard JK, Janning SW, Gass JS, Wilson RF "Cefuroxime-induced acute renal failure." Pharmacotherapy 14 (1994): 488-91</p><p id="ref_26">26. Manley HJ, Bailie GR, Eisele G "Bilateral renal cortical necrosis associated with cefuroxime axetil." Clin Nephrol 49 (1998): 268-70</p><p id="ref_27">27. Leong CL, Thiruventhiran T "Cefuroxime-induced acute renal failure." Nephron 84 (2000): 185</p><p id="ref_28">28. Cohen AD,  Cagnano E,  Halevy S "Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis." Int J Dermatol 40 (2001): 458-61</p><p id="ref_29">29. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_30">30. Mattes JA "Antabuse reaction with ceftin." Am J Psychiatry 163 (2006): 2019-20</p><p id="ref_31">31. Biteker M,  Duran NE,  Biteker FS, et al. "Kounis syndrome secondary to cefuroxime-axetil use in an octogenerian." J Am Geriatr Soc 56 (2008): 1757-1758</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Zinacef (cefuroxime)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Generic Availability</li>
<li>Drug class: second generation cephalosporins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Ceftin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Bladder Infection</li>
<li>Bone infection</li>
<li>Bronchitis</li>
<li data-more-config-id="list-data-resources-conditions">... +20 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cefuroxime: injectable powder for injection, intravenous solution, oral powder for reconstitution, oral tablet</i></p><h3>General</h3><p>Cefuroxime (the active ingredient contained in Zinacef) was generally well tolerated.  The side effects most commonly reported with the parenteral formulation have included neutropenia, eosinophilia, transient liver enzyme/bilirubin elevations, and injection site reactions.  The side effects most commonly reported with the oral formulations have included Candida overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances, and transient liver enzyme elevations.<sup>[Ref]</sup></p><p>Side effects may be more likely and more severe in patients with liver disease and/or renal dysfunction.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea/loose stools, nausea/vomiting, abdominal pain, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal cramps, flatulence, indigestion, mouth ulcers, swollen tongue, dyspepsia, gastrointestinal (GI) infection, ptyalism/excess salivation, GI disturbance, vomiting</p><p><b>Frequency not reported</b>: Abdominal discomfort, dry mouth, Clostridium difficile-associated diarrhea</p><p><b>Postmarketing reports</b>: GI disturbances (including diarrhea, nausea, vomiting, abdominal pain), pseudomembranous colitis</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Vomiting, abdominal pain, colitis<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transient increase in AST, transient increase in ALT, transient increase in liver enzyme levels</p><p><b>Uncommon</b> (0.1% to 1%): Transient increase in bilirubin</p><p><b>Postmarketing reports</b>: Hepatic dysfunction, hepatitis, cholestasis, jaundice (mainly cholestatic)</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Hepatic dysfunction (including cholestasis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Cephalosporin-class antibiotics (including this drug) have been associated with seizures, especially in patients with renal dysfunction when the dose was not reduced.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Headache, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Sleepiness, somnolence, hyperactivity</p><p><b>Postmarketing reports</b>: Seizures, encephalopathy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Delayed hypersensitivity reaction</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (including rash, pruritus, urticaria)</p><p><b>Rare</b> (0.01% to 0.1%): Severe hypersensitivity reactions</p><p><b>Frequency not reported</b>: Serum sickness</p><p><b>Postmarketing reports</b>: Anaphylaxis, serum sickness-like reaction<sup>[Ref]</sup></p><p>Delayed hypersensitivity reaction to this drug has been reported in 2.9% of patients with history of delayed hypersensitivity to penicillin (but not a cephalosporin).</p><p></p><p>Rare cases of severe hypersensitivity reactions (including erythema multiforme, toxic epidermal necrolysis [exanthematic necrolysis], drug fever, serum sickness-like reaction, anaphylaxis, Stevens-Johnson syndrome) have been reported.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Eosinophilia, decreased hemoglobin and hematocrit, neutropenia, decreased hemoglobin concentration</p><p><b>Uncommon</b> (0.1% to 1%): Positive Coombs test, leukopenia, thrombocytopenia</p><p><b>Frequency not reported</b>: Autoimmune granulocytopenia, increased coagulation time</p><p><b>Postmarketing reports</b>: Hemolytic anemia, pancytopenia, increased prothrombin time</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis<sup>[Ref]</sup></p><p>Profound leukopenia has sometimes been profound with oral therapy.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Increased BUN, increased creatinine, decreased CrCl, acute renal failure</p><p><b>Postmarketing reports</b>: Renal dysfunction, interstitial nephritis (including reversible fever, azotemia, pyuria, eosinophilia)</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Toxic nephropathy<sup>[Ref]</sup></p><p>Acute renal failure has been reported.  Renal function improved after this drug was stopped, and deteriorated upon rechallenge.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vaginitis</p><p><b>Uncommon</b> (0.1% to 1%): Vulvar itch, dysuria, vaginal candidiasis, vaginal discharge, vaginal itch, urethral pain/bleeding, kidney pain, urinary tract infection, vaginal irritation</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Vaginitis (including vaginal candidiasis)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Diaper/nappy rash</p><p><b>Uncommon</b> (0.1% to 1%): Rash, urticaria/hives, pruritus, erythema</p><p><b>Rare</b> (0.01% to 0.1%): Erythema multiforme, toxic epidermal necrolysis (exanthematic necrolysis), Stevens-Johnson syndrome</p><p><b>Frequency not reported</b>: Acute generalized exanthematous pustulosis</p><p><b>Postmarketing reports</b>: Angioedema, urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, cutaneous vasculitis<sup>[Ref]</sup></p><p>A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients.  The dermatitis resolved after the nurse stopped preparing the solutions.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p><p></p><p>Cephalosporin-class:</p><p>-Frequency not reported: Urine glucose false positive<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Transient increase in LDH, transient increase in alkaline phosphatase, Candida overgrowth, dislike of taste</p><p><b>Uncommon</b> (0.1% to 1%): Chest pain/tightness, chills, thirst, viral illness, candidiasis, fever</p><p><b>Rare</b> (0.01% to 0.1%): Drug fever</p><p><b>Frequency not reported</b>: Clostridium difficile overgrowth, disulfiram reaction<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Shortness of breath, sinusitis, cough, upper respiratory infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Muscle cramps, muscle stiffness, muscle spasm of the neck, lockjaw-type reaction, joint swelling, arthralgia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Tachycardia</p><p><b>Frequency not reported</b>: Kounis syndrome type I variant<sup>[Ref]</sup></p><p>A 90-year-old man, with no history of coronary artery disease, diabetes mellitus, hypertension, or hyperlipidemia, was administered 750 mg cefuroxime axetil IM for urinary tract infection.  About 10 minutes after the injection, the patient developed chest pain and pruritic skin rashes.  Kounis syndrome type I variant was diagnosed secondary to the drug.  Five days after stopping the drug, the patient's symptoms had resolved.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions (including pain, thrombophlebitis), thrombophlebitis with IV administration</p><p><b>Frequency not reported</b>: Pain at IM injection site<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Jarisch-Herxheimer reaction<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Irritable behavior</p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Bulpitt D, Potter CE, Jaderberg M "A large scale, general practice based investigation into the clinical efficacy and tolerability of cefuroxime axetil in women with uncomplicated urinary tract infect." Curr Med Res Opin 12 (1991): 318-24</p><p id="ref_3">3. Yangco BG, Lowe J, Nolen TM, et al "A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults." Clin Ther 12 (1990): 440-6</p><p id="ref_4">4. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ "Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis." Clin Ther 17 (1995): 861-74</p><p id="ref_5">5. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_6">6. Pines A, Raafat H, Kennedy MR, Mullinger BM "Experience with cefuroxime in 190 patients with severe respiratory infections." Chemotherapy 26 (1980): 212-7</p><p id="ref_7">7. Henry D, Ruoff GE, Rhudy J, Puopolo A, Drehobl M, Schoenberger J, Giguere G, Collins JJ "Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis." Antimicrob Agents Chemother 39 (1995): 2528-34</p><p id="ref_8">8. Cannon SR, Dyson PH, Sanderson PJ "Pseudomembranous colitis associated with antibiotic prophylaxis in orthopaedic surgery." J Bone Joint Surg Br 70 (1988): 600-2</p><p id="ref_9">9. Sommers D, Van Wyk M, Williams PE, Harding SM "Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing." Antimicrob Agents Chemother 25 (1984): 344-7</p><p id="ref_10">10. Hebblethwaite EM, Brown GW, Cox DM "A comparison of the efficacy and safety of cefuroxime axetil and augmentin in the treatment of upper respiratory tract infections." Drugs Exp Clin Res 13 (1987): 91-4</p><p id="ref_11">11. Holloway KL, Smith KW, Wilberger JE, Jemsek JG, Giguere GC, Collins JJ "Antibiotic prophylaxis during clean neurosurgery: a large, multicenter study using cefuroxime." Clin Ther 18 (1996): 84-94</p><p id="ref_12">12. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801</p><p id="ref_13">13. Griffiths GK, Vandenburg MJ, Wight LJ, et al "Efficacy and tolerability of cefuroxime axetil in patients with upper respiratory tract infections." Curr Med Res Opin 10 (1987): 555-61</p><p id="ref_14">14. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC. </p><p id="ref_15">15. Abramowicz M, Aaron H "Cefuroxime axetil." Med Lett Drugs Ther 30 (1988): 57-9</p><p id="ref_16">16. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ "Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia." J Antimicrob Chemother 37 (1996): 555-64</p><p id="ref_17">17. Baniasadi S,  Fahimi F,  Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):</p><p id="ref_18">18. Romano A, Quaratino D, Venuti A, Venemalm L, Mayorga C, Blanca M "Selective type-1 hypersensitivity to cefuroxime." J Allergy Clin Immunol 101 (1998): 564-5</p><p id="ref_19">19. Saeed SAM, Bazza M, Zaman M, Ryatt KS "Cefuroxime induced lymphomatoid hypersensitivity reaction." Postgrad Med J 76 (2000): 577-9</p><p id="ref_20">20. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226</p><p id="ref_21">21. Viken R, Van Arsdel PP "Allergy to cephalosporins." JAMA 265 (1991): 2254</p><p id="ref_22">22. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83</p><p id="ref_23">23. Murphy MF, Metcalfe P, Grint PC, et al "Cephalosporin-induced immune neutropenia." Br J Haematol 59 (1985): 9-14</p><p id="ref_24">24. Malloy CA,  Kiss JE,  Challapalli M "Cefuroxime-induced immune hemolysis." J Pediatr 143 (2003): 130-2</p><p id="ref_25">25. Goddard JK, Janning SW, Gass JS, Wilson RF "Cefuroxime-induced acute renal failure." Pharmacotherapy 14 (1994): 488-91</p><p id="ref_26">26. Manley HJ, Bailie GR, Eisele G "Bilateral renal cortical necrosis associated with cefuroxime axetil." Clin Nephrol 49 (1998): 268-70</p><p id="ref_27">27. Leong CL, Thiruventhiran T "Cefuroxime-induced acute renal failure." Nephron 84 (2000): 185</p><p id="ref_28">28. Cohen AD,  Cagnano E,  Halevy S "Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis." Int J Dermatol 40 (2001): 458-61</p><p id="ref_29">29. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_30">30. Mattes JA "Antabuse reaction with ceftin." Am J Psychiatry 163 (2006): 2019-20</p><p id="ref_31">31. Biteker M,  Duran NE,  Biteker FS, et al. "Kounis syndrome secondary to cefuroxime-axetil use in an octogenerian." J Am Geriatr Soc 56 (2008): 1757-1758</p><h2>More about Zinacef (cefuroxime)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Generic Availability</li>
<li>Drug class: second generation cephalosporins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Bladder Infection</li>
<li>Bone infection</li>
<li>Bronchitis</li>
<li data-more-config-id="list-data-resources-conditions">... +20 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>